Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BPhytohealth Corp. 〉PHN033 (Diabetic Nephropathy treatment)

PHN033 (Diabetic Nephropathy treatment)

PHN033 (Diabetic Nephropathy treatment)

The PHN033 project has been completed US FDA Phase IIa clinical trials for the treatment of diabetic nephropathy and was also chosen to be the Cross-Strait Drug Co-Development Project.The CFDA's guidelines-compliant CMC are underprepared

Request for Collaboration
Overview
Advantages of the product
  • Selection of native plants for control the medicinal origin and quality
  • Long-term human experience show no drug- related toxicity
  • Decreases serum AGEs and urine albumin concentration, The new drug with new mechanism of action .
  • Characteristic fingerprint to ensure superior quality control
  • Well-defined specifications to prove the consistency of quality among batches
Application
Prevention or treatment of diabetic nephropathy
Patent Portfolio
Patented for PHN033 in US, European Union , Australia, South Korea, Canada ,China, Japan and Taiwan.
Collaboration Options
  • Licensing
  • Co-development
People who like this also like
  • Platform_NanoX™Platform_NanoX™
  • TAH8801 Alzheimer's Disease Transdermal PatchTAH8801 Alzheimer's Disease Transdermal Patch
  • PeptidePeptide
  • Prenatal diagnosis by Oligonucleotide array-comparative genomic hybridization analysis testPrenatal diagnosis by Oligonucleotide array-comparative genomic hybridization analysis test
  • EG12014 Trastuzumab BiosimilarEG12014 Trastuzumab Biosimilar
  • TLC177TLC177
  • New combination for treating SialorrheaNew combination for treating Sialorrhea
  • HLX07HLX07
  • Burixafor (TG-3000)Burixafor (TG-3000)
  • FB825FB825